abrdn Life Sciences Investors
Last updated September 27, 2026
Organization details
- Legal name
- abrdn Life Sciences Investors
- Ownership
- Public
- Status
- Active
- Headquarters country
- United States
- Ticker symbol
- HQL
- Primary stock exchange
- NYSE
Identifiers
- SEC CIK
- 0000884121
Board of directors
- Since 2023
-
Daniel R. Omstead · Director · PresidentSince 2023
-
Kathleen Goetz · DirectorSince 2024
-
Rose DiMartino · DirectorSince 2023
-
Stephen Bird · DirectorSince 2023
- Since 2023
Board connections
6 of this board's directors also sit on 7 other boards.
- via Bill Maher, Daniel R. Omstead, Kathleen Goetz, Rose DiMartino, Stephen Bird and Todd Reit
- via Bill Maher, Kathleen Goetz, Rose DiMartino, Stephen Bird and Todd Reit
- via Bill Maher, Kathleen Goetz, Rose DiMartino, Stephen Bird and Todd Reit
- via Bill Maher
- via Todd Reit
- via Todd Reit
- via Todd Reit
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 28, 2025 | Saba Capital Management, L.P. 10% owner | Open-market sale | −3,602 | $12.95 | $46,646 |
| Mar 27, 2025 | Saba Capital Management, L.P. 10% owner | Open-market sale | −32,922 | $13.01 | $428,315 |
| Mar 24, 2025 | Weinstein Boaz 10% owner | Open-market sale | −2,329 | $13.21 | $30,766 |
| Feb 26, 2025 | Weinstein Boaz 10% owner | Open-market sale | −200 | $13.62 | $2,724 |
| Feb 13, 2025 | Weinstein Boaz 10% owner | Open-market sale | −100 | $13.88 | $1,388 |
| Feb 12, 2025 | Weinstein Boaz 10% owner | Open-market sale | −36,536 | $13.75 | $502,370 |
| Feb 11, 2025 | Saba Capital Management, L.P. 10% owner | Open-market sale | −19,756 | $13.77 | $272,040 |
| Feb 10, 2025 | Saba Capital Management, L.P. 10% owner | Open-market sale | −42,987 | $13.95 | $599,669 |
| Feb 4, 2025 | Weinstein Boaz 10% owner | Open-market sale | −4,065 | $14.05 | $57,113 |
| Feb 3, 2025 | Weinstein Boaz 10% owner | Open-market sale | −1,846 | $14.03 | $25,899 |
| Jan 31, 2025 | Weinstein Boaz 10% owner | Open-market sale | −15,143 | $14.27 | $216,091 |
| Jan 30, 2025 | Weinstein Boaz 10% owner | Open-market sale | −21,835 | $14.16 | $309,184 |
| Jan 29, 2025 | Weinstein Boaz 10% owner | Open-market sale | −11,674 | $14.12 | $164,837 |
| Aug 23, 2024 | Bill Maher Director | Open-market purchase | +650 | $15.37 | $9,991 |
| Jul 16, 2024 | Rose DiMartino Director | Open-market purchase | +1,000 | $15.53 | $15,530 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.